SR9009

SR9009 functions as a selective agonist of the REV-ERB alpha and beta nuclear receptors. These receptors are master regulators of circadian rhythms, mitochondrial biogenesis, and lipid metabolism. By binding to REV-ERBs, SR9009 activates the AMPK pathway, which increases cellular energy expenditure and fatty acid oxidation. This mechanism distinguishes it from SARMs that target androgen receptors directly. Research suggests that this modulation enhances mitochondrial density in muscle tissue, leading to improved aerobic endurance. The compound may also influence the expression of genes involved in muscle repair and oxygen transport. Because it does not significantly bind to androgen receptors, Stenabolic is not expected to cause the typical androgenic side effects associated with traditional steroids. However, its long-term impact on circadian rhythms and metabolic homeostasis remains an area of active investigation. Users report that the effects are subtle but consistent, particularly in endurance sports where sustained energy output is critical.

In research settings, SR9009 is primarily investigated for its role in enhancing endurance and aerobic capacity. It is frequently used in cutting phases to promote fat loss while preserving lean mass. Athletes report that it supports increased workout intensity and faster recovery between intervals. The compound is also studied for its potential cardiovascular benefits, including improved cardiac repair and protection against oxidative stress. Some researchers explore its use in recomposition cycles, where the goal is to reduce body fat while maintaining muscle mass. Due to its non-androgenic profile, it is often stacked with other SARMs or anabolic agents to complement its metabolic effects. It is not typically used for pure bulking purposes, as it does not significantly increase muscle protein synthesis. Instead, it is valued for its ability to optimize metabolic efficiency and oxygen utilization. Users in endurance sports, such as cycling and running, often cite it as a key component in their research protocols for improving performance metrics.

Commonly cited research protocols for SR9009 range from 10 mg to 30 mg per day. Intermediate users typically start at 10 mg daily to assess tolerance, while advanced users may increase to 20 mg or 30 mg daily. Cycle lengths generally span 8 to 12 weeks, with some protocols extending to 16 weeks. The compound is orally active and does not require injection. Due to its short half-life, it is often taken in two divided doses to maintain stable plasma levels. It is important to note that Stenabolic is not a prodrug and is metabolized quickly. Users report that higher doses do not necessarily yield linearly greater benefits, suggesting a plateau in efficacy. Stacking with other compounds may require careful dosing adjustments to avoid excessive metabolic stress. As with all research compounds, individual responses vary, and titration is recommended. There is no established PCT protocol specific to SR9009 alone, but standard monitoring is advised when used in multi-compound stacks.

The side effect profile of SR9009 is generally considered mild compared to traditional anabolic steroids. However, users report potential suppression of natural testosterone production, particularly at higher doses or when stacked with other suppressive compounds. This suppression may necessitate post-cycle therapy (PCT) to restore hormonal balance. Hepatotoxicity is a concern with oral compounds, and regular liver function tests are recommended. Other reported side effects include changes in sleep patterns due to circadian rhythm modulation and potential impacts on lipid profiles. Cardiovascular monitoring is advised, as the compound affects cardiac metabolism. Long-term safety data is limited, and research should be conducted with caution. Users should be at least 21 years old and have a baseline blood panel before starting. Discontinuation should be gradual to minimize rebound effects. While SR1078 is not classified as a controlled substance in many regions, its legal status varies by jurisdiction. Prioritizing blood work and monitoring for any adverse reactions is essential for safe research use.

Mechanism of action

SR9009 acts as a selective agonist of REV-ERB nuclear receptors, modulating mitochondrial biogenesis, lipid metabolism, and circadian rhythms to enhance aerobic endurance and fatty acid oxidation.